ADAPTIVEMOBILE-SECURITY
12.9.2019 09:09:08 CEST | Business Wire | Press release
Following extensive research, AdaptiveMobile Security, a world leader in cyber-telecoms security, today announced it has uncovered a new and previously undetected vulnerability. This vulnerability is currently being exploited and is being used for targeted surveillance of mobile phone users. The vulnerability and its associated attacks have been named, ‘Simjacker’ as it involves the hijacking of SIM cards and threatens mobile phone users across the globe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190912005038/en/
Simjacker extracts the location information of mobile phone users from vulnerable operators, retrieved using malicious SMS messages. The location information of thousands of devices was obtained over time without the knowledge or consent of the targeted mobile phone users. Based on previous intelligence, it is likely that these attacks originated from a surveillance company which works with governments, to track and monitor individuals; bypassing existing signalling protection.
Cathal Mc Daid, Chief Technology Officer of AdaptiveMobile Security explained, “Simjacker represents a clear danger to the mobile operators and subscribers. This is potentially the most sophisticated attack ever seen over core mobile networks. It’s a major wake-up call that shows hostile actors are investing heavily in increasingly complex and creative ways to undermine network security. This compromises the security and trust of customers, mobile operators and impacts the national security of entire countries.”
While the primary attack detected involved the retrieval of mobile phone locations, Simjacker has been further exploited to perform many other types of attacks against individuals and mobile operators such as fraud, scam calls, information leakage, denial of service and espionage. AdaptiveMobile Security Threat Intelligence analysts observed the hackers vary their attacks, testing many of these further exploits.
In theory, all makes and models of mobile phone are open to attack as the vulnerability is linked to a technology embedded on SIM cards. AdaptiveMobile Security research indicates that the Simjacker vulnerability could extend to over 1 billion mobile phone users globally, potentially impacting countries in North and South America, West Africa, Europe, Middle East and indeed any region of the world where this SIM card technology is in use.
Mc Daid continued, “Simjacker worked so well and was being successfully exploited for years because it took advantage of a combination of complex interfaces and obscure technologies, showing that mobile operators cannot rely on standard established defences. Now that this vulnerability has been revealed, we fully expect the exploit authors and other malicious actors will try to evolve these attacks into other areas”.
AdaptiveMobile Security has been working closely with their customers and the wider industry; including both mobile network operators and SIM card manufacturers to protect mobile phone subscribers. AdaptiveMobile Security are committed to using their global threat intelligence to build defences against these new sophisticated attacks that are circumventing current security measures.
Further details on Simjacker are available on www.simjacker.com and Cathal Mc Daid, Chief Technology Officer of AdaptiveMobile Security will be presenting on Simjacker at the Virus Bulletin Conference, London, 3 October 2019.
---Ends---
About
AdaptiveMobile Security is the world leader in cyber-telecoms security, protecting over 2.1 billion subscribers worldwide. The combination of global insight provided by our security specialists teams, our world-leading Threat Intelligence Unit and our proprietary, telecom-grade Network Protection Platform are trusted by the world’s largest service providers to secure their critical communications infrastructure.
The Company HQ is in Dublin with offices in North America, Europe, South Africa, the Middle East and Asia Pacific.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190912005038/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom